ALIZE PHARMA AZP-531/UAG program
Prior to its acquisition by Millendo Therapeutics in December 2017, Alizé Pharma SAS was focused on the development of livoletide (AZP-531), an unacylated ghrelin analog, for the treatment of Prader-Willi syndrome.
- Allas S, Caixas A, Poitou C, et al. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial. PLOS ONE, in press 2018.